How Foundayo was developed: from Chugai molecule to Lilly's ATTAIN trials

Foundayo is a weight-loss tablet that reached patients in the United States in April 2026 and the United Kingdom in August 2026. Its story is longer than that single date suggests: a molecule discovered in Japan, licensed to a US company nearly a decade earlier, and carried through a large trial programme before any regulator saw an application. This page sets out where the drug came from, who makes it, why its chemistry matters, and what the trials actually found.

Who makes Foundayo?

Foundayo is made by Eli Lilly and Company. Its generic (non-brand) name is orforglipron, and its drug class is a once-daily oral small-molecule (non-peptide) GLP-1 receptor agonist. In plain terms, it is a tablet that acts on the same GLP-1 pathway as injectable weight-loss medicines, but it is a chemically synthesised small molecule rather than a peptide, which is why it can be made into a pill.

Lilly filed the drug with the US Food and Drug Administration under application number NDA 220934, and the FDA approved it on 1 April 2026. When people ask "who makes Foundayo", the short answer is Eli Lilly — but Lilly did not invent the molecule itself.

The molecule's origin: a Chugai discovery, licensed to Lilly

Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd., a Japanese company. Eli Lilly licensed the molecule from Chugai in 2018 and took over its development. This is a common pattern in the pharmaceutical industry: one firm identifies a promising compound, and a larger developer with the resources to run global trials and manufacture at scale takes it forward.

That division of labour matters for understanding the orforglipron development timeline. The molecule was not created inside Lilly's own laboratories; it was in-licensed and then put through years of clinical testing — the phase 3 ATTAIN programme described below — before any approval was possible.

Why an oral small-molecule GLP-1 matters

Most GLP-1 medicines to date have been peptides — large, delicate molecules that are usually given by injection because the digestive system would otherwise break them down. The one widely used peptide GLP-1 in pill form, Rybelsus (oral semaglutide), comes with strict rules: it must be taken on an empty stomach with only a small sip of plain water, and the person then has to wait about half an hour before eating, drinking or taking anything else, so that enough of the drug is absorbed.

Orforglipron is different because it is a small molecule, not a peptide. It survives the gut well enough that, according to Lilly, it can be taken any time of day, with no food or water restrictions — the company describes it as the only GLP-1 pill for weight loss that can be taken at any time without those restrictions.

The chemistry also shapes how the drug can be manufactured, and this is arguably the most important point in the whole development story. A small-molecule tablet can be synthesised chemically and produced far more cheaply and at much higher volume than an injectable peptide, which needs fermentation or complex peptide synthesis. That difference in scalability is the foundation of Lilly's plan to supply an oral GLP-1 to a mass market — and, as set out below, the reason the company committed billions of dollars to new factories.

The ATTAIN trial programme

Before an approval, orforglipron had to show that it worked and was tolerable. That evidence came from Lilly's phase 3 ATTAIN trials. Two of these have reported detailed results.

A note on the numbers: the ATTAIN trials tested research doses labelled 6 mg, 12 mg and 36 mg. These are not the same as the six prescribing strengths the tablet is now sold in (0.8 mg up to 17.2 mg), which are reached through a slow, month-by-month titration. If you are looking at how Foundayo is dosed and titrated, keep the two numbering systems separate.

ATTAIN-1: adults with obesity, without type 2 diabetes

ATTAIN-1 was a 72-week, randomised, double-blind, placebo-controlled trial in 3,127 adults who had obesity, or overweight with weight-related health problems, but not type 2 diabetes. It ran across ten countries and compared the three doses against placebo, alongside diet and increased physical activity.

At the highest dose (36 mg), average body-weight change at 72 weeks was −12.4% (about −12.4 kg, or −27.3 lb), compared with −0.9% on placebo. Around 39.6% of people on the top dose lost at least 15% of their body weight, against 3.6% on placebo. The trial also reported improvements in cholesterol, triglycerides and blood pressure. These results were published in the New England Journal of Medicine.

ATTAIN-2: adults who also have type 2 diabetes

ATTAIN-2 was a separate 72-week trial in more than 1,600 adults with obesity or overweight plus type 2 diabetes. At the 36 mg dose, average weight loss was −10.5% (about −22.9 lb) versus −2.2% on placebo, and blood-sugar control (HbA1c) fell by up to 1.8 percentage points from a baseline of 8.1%.

Weight loss in people with type 2 diabetes (−10.5%) was somewhat lower than in people without it (−12.4%). That is not a contradiction between the two trials — it is a pattern seen right across the GLP-1 class, in which weight loss tends to be a little smaller when diabetes is present.

FDA approval in April 2026

The FDA approved Foundayo on 1 April 2026 for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and keep it off long term, alongside a reduced-calorie diet and more physical activity.

The approval itself was unusually fast. Foundayo was the fifth medicine — and the first new molecular entity — cleared under the FDA Commissioner's National Priority Voucher pilot, a scheme designed to speed up review of selected medicines. It was approved roughly 50 days after filing and 294 days ahead of its scheduled decision date, described as the fastest approval of a new molecular entity since 2002. A fast review is about administrative priority; it does not change the underlying trial evidence, which was gathered over the preceding years.

Building the supply: Lilly's manufacturing investment

Because orforglipron is a tablet that can be made at scale, Lilly's development story is also a manufacturing story. To build the capacity to supply an oral GLP-1 to large numbers of patients, the company announced a series of large investments, reported through its own announcements and the business press:

• A $6 billion plant in Huntsville, Alabama (announced December 2025), explicitly tied to the obesity pill.
• An oral-medicines facility in Katwijk, the Netherlands, of roughly $3 billion (€2.6 billion).
• A $3 billion expansion in China, directed largely at orforglipron capacity.

These sit within a broader Lilly global manufacturing programme reported at around $27 billion, together with supplementary contract-manufacturing deals. The scale of that spending only makes sense for a product the company expects to make and sell in very large volumes — which, again, comes back to the small-molecule chemistry that makes high-volume tablet production possible.

A word on side effects

No development summary is complete without safety. In the ATTAIN trials the most common side effects were gastrointestinal — mainly nausea, constipation, diarrhoea and vomiting — usually mild to moderate, more frequent at higher doses, and typical of the GLP-1 class. The FDA-approved labelling also carries a boxed warning about a risk of thyroid tumours based on animal studies, and lists contraindications and other precautions that a prescriber would assess. We cover this in full on our Foundayo side effects page.

For UK patients, the authority on warnings and contraindications is the UK Summary of Product Characteristics, published on the electronic medicines compendium (emc) following the MHRA licence, together with the patient information leaflet in the box. If you experience a side effect from any medicine, you can report it through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk, and you should speak to your GP or pharmacist.

Where UK approval stands

Everything above describes the US approval — but the UK followed quickly. On 10 August 2026 the MHRA licensed orforglipron for weight management and for type 2 diabetes, making the UK the first country in Europe to authorise it. On 24 August 2026 Lilly UK announced that Foundayo is available in the UK via private prescription. NHS funding is a separate step: NICE is appraising the medicine for managing overweight and obesity, with guidance expected on 18 November 2026, and until then it is not available on the NHS. You can read our full, regularly updated summary on the Foundayo UK availability page.

Foundayo is a prescription-only medicine. Any site claiming to supply it in Britain without a consultation and prescription from a qualified prescriber is operating illegally, and its products should be treated as unsafe.

Frequently asked questions

Who makes Foundayo?

Eli Lilly and Company makes Foundayo. The molecule, orforglipron, was discovered by Chugai Pharmaceutical in Japan and licensed to Lilly in 2018; Lilly ran the clinical development and holds the FDA approval.

What does "oral small-molecule GLP-1" mean?

It means the drug acts on the GLP-1 pathway (like injectable weight-loss medicines) but is a small, chemically made molecule rather than a peptide. That is why it can be swallowed as a tablet and, according to Lilly, taken any time of day without food or water restrictions.

What did the ATTAIN trials show?

In ATTAIN-1 (adults with obesity, no diabetes), the top 36 mg dose produced about 12.4% average weight loss over 72 weeks versus 0.9% on placebo. In ATTAIN-2 (adults who also had type 2 diabetes), the top dose produced about 10.5% weight loss and reduced HbA1c by up to 1.8 points.

Can I buy Foundayo in the UK now?

Yes, by private prescription only. Foundayo was licensed by the MHRA on 10 August 2026 and has been available in the UK by private prescription since 24 August 2026; it is not available on the NHS. It is a prescription-only medicine, so a prescriber decides whether it is suitable — any website offering it without a prescription is acting illegally and its products are unsafe.

References

1. Eli Lilly and Company. "FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss…" Lilly investor news release. investor.lilly.com
2. Aronne LJ et al. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist" (ATTAIN-1). New England Journal of Medicine. nejm.org
3. Eli Lilly and Company. "Lilly's oral GLP-1 orforglipron successful in third Phase 3 trial" (ATTAIN-2). Lilly investor news release. investor.lilly.com
4. US Food and Drug Administration. Approval letter, NDA 220934 (Foundayo / orforglipron), 2026. accessdata.fda.gov
5. Medicines and Healthcare products Regulatory Agency. "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes." 10 August 2026. gov.uk
6. Eli Lilly and Company (UK). Press releases — Foundayo available in the UK via private prescription, 24 August 2026. lilly.com/uk
7. National Institute for Health and Care Excellence. Orforglipron for managing overweight and obesity — appraisal in development (GID-TA11650). nice.org.uk

Manufacturing investment figures (Huntsville, Katwijk, China and the wider programme) and the Chugai licensing history are drawn from Eli Lilly's own announcements and contemporaneous business reporting, as compiled in this site's research notes. Figures are cited to those sources rather than reproduced from any pharmacy or commercial vendor.